Prescriptions for the antiviral drug Paxlovid have soared for the reason that treatment was granted emergency use authorization final December. Excessive-profile individuals who lately examined constructive—together with President Joe Biden, White Home medical advisor Dr. Anthony Fauci, and late evening host Stephen Colbert—have additionally taken the drug.

However some folks—together with these three well-known sufferers—have reported rebound infections after taking the drugs. Paxlovid rebound happens when an individual takes the drug for just a few days, exams detrimental, after which exams constructive once more a number of days later.

The rising variety of instances is prompting questions on whether or not folks needs to be taking Paxlovid for longer durations of time to keep away from rebound infections. Right here’s what virologists and the newest research say.

How frequent is Paxlovid rebound?

Researchers have established that individuals who take a look at constructive after ending a five-day course of Paxlovid usually are not contracting a brand new an infection. Genetic research present that the virus that comes again quickly after an individual stops therapy is identical one which precipitated the preliminary an infection. Nevertheless it’s not but clear how frequent rebound infections are. Within the authentic research submitted to the U.S. Meals and Drug Administration (FDA) for emergency use authorization, Paxlovid’s drugmaker Pfizer discovered that rebounds occurred in 1-2% of sufferers—the identical fee as within the placebo group.

Dr. David Ho, professor of drugs and director of the Aaron Diamond AIDS Analysis Heart at Columbia College, is learning Paxlovid rebound and believes the prevalence is probably going larger. “In my very own expertise, I’ve now counted 15 mates, relations, and colleagues who’ve taken Paxlovid, and over half have rebounded,” he says. Although that’s not a scientific tally, “physicians with giant COVID-19 practices will inform you that it’s not uncommon.”

Determining precisely how typically rebound happens could not occur any time quickly. If rebound doesn’t often happen, tens of hundreds of individuals taking the drug must be adopted in an effort to adequately decide how typically folks take a look at constructive once more. “I’m afraid that may by no means be accomplished,” says Dr. Mark Siedner, a scientific epidemiologist at Massachusetts Normal Hospital and affiliate professor of drugs at Harvard Medical Faculty, who has studied sufferers with Paxlovid rebound.

To get at the least some thought of the frequency, Siedner’s group is enrolling just a few hundred folks in a examine that may hopefully shed some gentle on the query. The volunteers will get their noses swabbed 3 times per week and the researchers will analyze the samples to search for any stay virus, and if viruses are current, develop them to see in the event that they proceed to stay lively and infectious. His crew has already accomplished a small examine displaying that individuals with Paxlovid rebound stay contagious once they take a look at constructive the second time, which suggests they should prolong their isolation interval for an additional 5 days at the least, and proceed sporting masks throughout that point if they arrive into contact with different folks.

Absent giant and conclusive knowledge, Siedner says well being officers on the FDA must weigh the advantages and dangers of Paxlovid in contemplating whether or not medical doctors ought to be capable to prescribe an extended course of therapy.

The case for longer therapy

Is there justification for an extended course of therapy? “In my thoughts, there may be,” says Ho—who, along with learning Paxlovid rebound, has skilled it himself. In research, Ho says he’s noticed that Paxlovid does its job of suppressing SARS-CoV-2, halting the virus from persevering with to copy and primarily trapping it in an middleman type. This model of the virus isn’t totally shaped, and wishes just a few extra steps of growth earlier than it turns into lively and may infect new cells. Paxlovid suppresses the virus at this stage. However in Ho’s research, the half lifetime of the virus on this suspended state is almost a day—anyplace from 19 to 22 hours—which suggests it takes that lengthy for about half of the virus to decay. For somebody who’s contaminated, if there may be nonetheless sufficient of this middleman type within the physique after the fifth and closing day of Paxlovid therapy, that virus may reactivate, end its growth, and begin infecting cells anew—thus inflicting a rebound an infection.

“The virus is quite persistent,” says Ho. “And we consider that 5 days of therapy isn’t sufficient to have that type decay in order that it’s nonexistent on the finish of these 5 days.”

Based mostly on his lab outcomes, Ho’s crew calculated that extending Paxlovid for a number of extra days—three to 5 days past the present routine—may cut back the chance of rebound by 10-fold. The extra few days would remove extra of the middleman type of the virus circulating within the physique. Extra research are wanted to validate that, says Ho, and to substantiate that extending the drug for a number of extra days is protected.

Paxlovid isn’t the one antiviral drug that acts this manner. Paxlovid is a protease inhibitor—that means it interferes with the virus’ capability to type the ultimate proteins it wants—and different medicines that belong to this class of medication trigger related an infection rebounds. For instance, says Ho, ensitrelvir, a SARS-CoV-2 antiviral that the Japanese pharmaceutical firm Shionogi is learning, produced related intermediaries that hadn’t deteriorated earlier than the drug was stopped and bounced again to trigger an infection once more. “It’s associated to the mechanism of motion of the drug, not associated to a deficit in [Paxlovid],” says Ho.

It’s much like the way in which antibiotics work: if folks cease taking antibiotics earlier than the prescribed time interval is up, the an infection can return earlier than the sufficient of the micro organism is eradicated. “We’ve definitely seen infections the place in the event you give the therapy, you knock down the extent of micro organism or virus, however in the event you don’t fully eradicate it—after which it comes roaring again,” Siedner says. With Paxlovid rebound, “my guess is that it’s taking place as a result of folks aren’t getting handled lengthy sufficient.”

Some folks contaminated with SARS-CoV-2 who haven’t taken Paxlovid have even skilled rebound infections, through which they take a look at detrimental and assume they’ve recovered, however then take a look at constructive a number of days later, Siedner says. However the conditions are completely different. “Individuals with Paxlovid rebound have a lot larger viral hundreds, the viral load stays excessive for a for much longer time frame, and the signs last more,” in comparison with individuals who rebound and haven’t taken the drug, he says. “Paxlovid rebound is the true deal.”

In an announcement, a Pfizer spokesperson stated that as a result of the corporate’s preliminary research discovered related rebound charges within the therapy and placebo teams, these knowledge “counsel the return of elevated detected nasal viral RNA (also referred to as viral rebound or COVID-19 rebound) is rare and never uniquely related to any particular therapy.”

Ho notes, nonetheless, that these research weren’t particularly designed to detect and measure rebound, and that extra detailed analyses are wanted.

Apart from taking an extended course of Paxlovid, an alternative choice for addressing rebound could be to permit sufferers to begin a second course of Paxlovid as soon as they take a look at constructive once more, consultants say. The Pfizer spokesperson confirmed that the corporate is working with the FDA to arrange a trial learning this.

The case towards an extended course of therapy

Like every drug, Paxlovid has uncomfortable side effects—the most typical of which is an especially dangerous style within the mouth that briefly impacts some folks’s capability to eat. The treatment additionally interacts with various different often used medicine, together with cholesterol-lowering statins. “We regularly ask folks to carry off on a few of their different medicines or lower doses of their medicines for 5 days whereas taking Paxlovid,” says Dr. Davey Smith, professor of drugs at College of California, San Diego, who has studied Paxlovid rebound in sufferers. “Asking them to carry off longer could have extra dangers and outweigh the advantages of doing that. There are a complete bunch of problems in simply asking any individual to take the drug for 7 or 10 days.”

Siedner additionally notes that when the advantages versus the dangers of longer remedy, medical doctors want to contemplate how a lot individuals who rebound are impacted by the second an infection. In a examine from Kaiser Permanente of greater than 5,000 individuals who took Paxlovid, fewer than 1% ended up within the hospital due to their signs—together with those that rebounded. “By and huge, the well being report techniques usually are not seeing large numbers of individuals needing hospitalization that might be averted with longer therapy,” he says. “If rebound isn’t taking place that always, and individuals who rebound aren’t at larger danger of hospitalization than individuals who had not taken Paxlovid, then I believe there will not be a lot profit to giving everybody an extended course of therapy.”

One other worry of extending the course of Paxlovid is that SARS-CoV-2 may doubtlessly grow to be proof against the drug. Ho reported the primary proof of this in a paper printed Aug. 8 in pre-print type on the bioRxiv server. In lab research, he and his crew discovered that when the virus was challenged with doses of Paxlovid, it developed a number of pathways to evading the drug, elevating considerations about the necessity to design next-generation antivirals or to make use of them together, as medical doctors presently do to regulate HIV. Extra research are wanted to doc how shortly the virus develops resistance to Paxlovid and whether or not extending the remedy by just a few days would improve this danger.

Is it nonetheless price taking Paxlovid?

For individuals who have danger components that make them extra susceptible to COVID-19, medical doctors proceed to say that the advantages of Paxlovid outweigh the chance of rebound, for the reason that drug protects folks from getting sick sufficient to wish hospitalization and from dying of COVID-19. Most individuals experiencing rebound report comparatively delicate signs and don’t require extra intensive medical care. Even when some folks received’t be capable to suppress their an infection fully after a course of Paxlovid, the therapy should still be serving to them to keep away from extra severe illness. As extra knowledge grow to be out there, well being officers could reevaluate how lengthy that spherical of therapy must be.

Extra Should-Learn Tales From TIME


Contact us at letters@time.com.